Evaluating plasma phosphorylated tau217 for clinical rule-out of cerebral amyloid pathology: Evidence from a memory clinic cohort.

Authors

Carolin I Kurz, Paulina Tegethoff, Anna Hufnagel, Robert Perneczky

Published in

Journal of Alzheimer's disease : JAD. Pages 13872877261500407. Nov 01, 2026. Epub Nov 01, 2026.

Abstract

BackgroundPlasma phosphorylated tau 217 (pTau217) is a promising biomarker for Alzheimer's disease amyloid-β (Aβ) pathology, but cut-offs require validation.ObjectiveThe aim was to evaluate the diagnostic performance of plasma phosphorylated tau 217 for identifying cerebral amyloid pathology to reduce the need for more invasive or resource-intensive confirmatory testing by identifying individuals with a low likelihood of amyloid pathology.MethodsElecsys^® pTau217 was evaluated in a memory clinic cohort using ROC analysis. Cut-offs were derived using sensitivity-weighted Euclidean distance and bootstrap resampling.ResultspTau217 discriminated Aβ-positive from Aβ-negative individuals (AUC 0.854). The cut-off was 0.169 pg/mL (95% CI 0.140-0.200), with 87.7% sensitivity and 77.0% specificity. Age and sex adjustment did not improve performance.ConclusionsThe threshold was consistent with previously reported low cut-offs, supporting potential rule-out utility; however, its sensitivity precludes stand-alone exclusion of Aβ pathology in memory clinic populations.

PMID:
42968340
Bibliographic data and abstract were imported from PubMed on 02 Nov 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.